



## Shattuck Labs Announces Participation in Upcoming March Investor Conferences

February 23, 2021

AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Shattuck management will participate in two upcoming investor conferences.

### Presentation Details

Conference: Cowen 41st Annual Health Care Conference  
Format: Ovarian Cancer Panel discussion  
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer  
Date: March 2, 2021  
Time: 12:50 p.m. EST  
Webcast Link: The panel discussion will be available live to conference attendees

Conference: Oppenheimer 31st Annual Healthcare Conference  
Presenter: Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy  
Date: March 16, 2021  
Time: 11:20 a.m. EST  
Webcast Link: Available [Here](#)

The live webcast of the Oppenheimer presentation will be available on the [Events & Presentations](#) section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

### About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC<sup>®</sup>, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRP $\alpha$ -Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN<sup>™</sup>, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

### Investor Contact:

Conor Richardson  
Senior Director, Finance & Investor Relations  
Shattuck Labs, Inc.  
[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

### Media Contact:

Stephanie Ascher  
Managing Director  
Stern Investor Relations, Inc.  
[Stephanie.ascher@sternir.com](mailto:Stephanie.ascher@sternir.com)



Source: Shattuck Labs, Inc.